How the mTOR Pathway Rebuilds Cortical Synapses to Drive Rapid Antidepressant Responses

Traditional psychiatry models depression as a chemical imbalance—a deficit of serotonin or dopamine that requires weeks of daily medication to correct by slowly downregulating receptors. Conversely, neuroplasticity researchers model depression as a structural loss—a physical withering of synaptic connections in the prefrontal cortex caused by chronic stress. In this second framework, rapid-acting agents like ketamine and psilocybin do not simply mask symptoms; they physically rebuild the missing neural architecture in a matter of hours.[9]

The stakes for resolving this mechanistic debate are immense. Millions of patients with treatment-resistant depression fail to respond to standard selective serotonin reuptake inhibitors (SSRIs). The clinical discovery that a single dose of an NMDA antagonist or a serotonergic psychedelic can lift depressive symptoms within 24 hours has forced a reevaluation of how depression functions at the cellular level, shifting the focus from correcting chemicals to rebuilding hardware.[2][9]

The biological bridge between a receptor blockade and a newly formed synapse is the mammalian target of rapamycin (mTOR). mTOR is a highly conserved protein kinase that acts as a master switch for cellular growth and protein synthesis. When activated, it signals the neuron to begin manufacturing the structural proteins required to extend new dendritic spines, effectively wiring new pathways in the brain.[4][7]

The foundational evidence for this pathway emerged when researchers demonstrated that ketamine rapidly activates mTOR signaling in the prefrontal cortex. By blocking NMDA receptors on inhibitory interneurons, ketamine triggers a sudden, localized surge of glutamate—the brain's primary excitatory neurotransmitter, which is present in over 60 percent of all brain synapses.[1][8]

This glutamate surge then activates a different class of receptors to initiate the growth phase. Research published in the journal eLife shows that ketamine's rapid antidepressant effects are specifically mediated by calcium-permeable AMPA receptors. When these specific AMPA receptors are stimulated by the glutamate surge, they trigger the intracellular calcium influx necessary to flip the mTOR switch to its active state.[5]

Once mTOR is activated, the structural rebuilding begins immediately. "We observed that ketamine rapidly activated the mammalian target of rapamycin (mTOR) pathway, leading to increased synaptic signaling proteins and increased number and function of new spine synapses in the prefrontal cortex of rats," wrote researchers in a landmark 2010 paper in Science.[1]

While ketamine acts directly on the glutamate system, serotonergic psychedelics like psilocybin and LSD primarily target the 5-HT2A serotonin receptor. Yet, clinical observations show they produce a nearly identical rapid antidepressant response. This raised a critical question: how do two entirely different classes of drugs, binding to different primary receptors, produce the same 24-hour structural reset?[2][3]

A 2021 review in Oxford Academic highlighted that despite their distinct primary targets, both drug classes converge on the exact same downstream neuroplasticity mechanisms. The activation of the 5-HT2A receptor by psilocybin ultimately leads to downstream glutamate release, subsequent AMPA receptor potentiation, and the identical activation of the mTORC1 complex.[2]

Recent evidence has expanded this convergence beyond just synaptic proteins to include the immune system. A July 2026 study published in Molecular Psychiatry found that both ketamine and psychedelics trigger a shared neuroimmune signaling network. The researchers identified 103 specific proteins altered in spinal fluid after ketamine administration, and found that 86 percent of those same proteins were also altered by serotonergic psychedelics.[6]

This 2026 study identified interleukin-15 (IL-15) and MCP-1 as central regulatory hubs linking immune activity to neural function. Patients who successfully responded to ketamine showed specific baseline immune profiles—lower IL-15 pathway activity and elevated B-cell signaling—that reversed after treatment, suggesting that restoring immune balance is inextricably linked to the structural rebuilding of synapses.[6]

The primary clinical limitation of this structural reset is its durability. The new dendritic spines formed by mTOR activation are not permanent fixtures. Clinical data consistently shows that ketamine's antidepressant effects typically fade after 7 to 14 days, requiring repeated infusions or ongoing therapeutic support to maintain the synaptic gains and prevent the neural architecture from withering again under the pressure of chronic stress. For patients exploring these therapies, this means viewing them not as a permanent cure, but as a temporary window of profound neuroplasticity during which behavioral and psychological habits can be reshaped.[4][9]

Because both ketamine and psilocybin carry profound dissociative and hallucinogenic effects, pharmaceutical development is now attempting to bypass the upstream receptors entirely. The objective is to develop direct mTORC1 activators that can trigger the necessary synaptogenesis without the psychoactive experience. Safely targeting a master cellular growth switch remains a significant pharmacological hurdle, but the blueprint for rapid structural recovery is now firmly established.[4][8]